Search

Displaying results 1081 - 1090 of 1786 in total
  1. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]

  2. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    FDA approved on December 24, 2008.

  3. Drug

    Terlipressin

    go.drugbank.com/drugs/DB02638
    ApprovedInvestigational

    [A252672] The drug was first approved by the FDA in September 2022.[L43217]

  4. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

  5. Drug

    Levomilnacipran

    go.drugbank.com/drugs/DB08918
    ApprovedInvestigational

    [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.

  6. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract

  7. Drug

    Trimebutine

    go.drugbank.com/drugs/DB09089
    ApprovedInvestigational

    Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries.

  8. Drug

    Benzoyl peroxide

    go.drugbank.com/drugs/DB09096
    ApprovedInvestigational

    [A234059,A234064,A234069] Benzoyl peroxide, in combination with erythromycin, was granted FDA approval on 26 October 1984.[L33264]

  9. Drug

    Potassium gluconate

    go.drugbank.com/drugs/DB13620
    Approved

    Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. It is also used as a potassium supplement [L2657]. Potassium is an essential nutrient.

  10. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.